This report provides a comprehensive analysis of the global Forzeset Tablets market, focusing on its role as a selective KRAS G12C inhibitor for treating advanced non-small cell lung cancer. The study examines market dynamics, including the impact of medical insurance inclusion and shifting competition from availability to clinical superiority. Detailed forecasts cover growth through 2032, segmented by type, application, sales channel, and geography, while evaluating key players and strategic trends across the Americas, APAC, Europe, and MEA.

Market Overview

The global Forzeset Tablets market is projected to experience significant growth, increasing from US$ 19.56 million in 2025 to US$ 104 million by 2032, representing a compound annual growth rate (CAGR) of 11.6% from 2026 to 2032. In 2025, global production of Fulzerasib Tablets reached approximately 12,000–15,000 bottles.

Product Profile: Fulzerasib Tablets

Fulzerasib Tablets is an oral, highly selective, and irreversible KRAS G12C inhibitor.

• Mechanism of Action: The drug works by covalently binding to the cysteine residue of the mutant protein, which locks the KRAS protein in an inactive conformation. This process blocks the transduction of the downstream MAPK signaling pathway, thereby inhibiting tumor cell proliferation and survival.
• Indications: It is primarily indicated for the treatment of locally advanced or metastatic non‑small cell lung cancer (NSCLC) that harbors the KRAS G12C mutation.
• Clinical Significance: It provides a new domestic targeted therapy option for Chinese patients suffering from advanced lung cancer harboring the KRAS G12C mutation.

Market Dynamics and Strategic Analysis

Growth Drivers and Market Evolution

As the first domestically approved KRAS G12C inhibitor in China, Fulzerasib has established an early market lead in treating advanced non‑small cell lung cancer, effectively filling a critical gap in China's targeted therapy landscape for this specific target.

Key factors influencing market development include:

• Medical Insurance and Payment Systems: The inclusion of the drug in medical insurance, accompanied by substantial price reductions, has significantly lowered barriers to access, improving both availability and clinical penetration.
• Shift in Competition: As the domestic KRAS G12 inhibitor sector enters a volume‑expansion stage following medical insurance inclusion, the competitive focus has shifted from mere "availability" to "superiority."

Competitive Landscape and Future Outlook

An intense competitive landscape among similar domestic drugs has emerged. To maintain a competitive edge, Fulzerasib must develop differentiated advantages in the following areas:

• Pricing Strategies
• Indication Expansion
• Combination Therapy Regimens: Leveraging clinical efficacy, safety profiles, and commercialization networks.

Future market growth will be contingent upon the depth of medical insurance coverage, progress in expanding indications, clinical recognition, and the strength of commercial execution capabilities.

Report Scope and Methodology

The “Forzeset Tablets Industry Forecast” by LP Information, Inc. (LPI) provides a comprehensive analysis of the global industry. The report reviews total world sales in 2025 and provides detailed projections for 2026 through 2032, broken down by region, market sector, and sub-sector in US$ millions.

Key Analytical Focus Areas:

• Market Trends: Product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Corporate Strategy: Analysis of leading global companies regarding their Forzeset Tablets portfolios, capabilities, market entry strategies, market positions, and geographic footprints.
• Market Drivers: Evaluation of key trends, drivers, and affecting factors shaping the global outlook.
• Methodology: A transparent approach based on hundreds of bottom-up qualitative and quantitative market inputs to provide a nuanced view of the current state and future trajectory.

Market Segmentation

By Type

• 150mg
• 500mg

By Combination Therapy

• Combined With Immune Checkpoint Inhibitors
• Combined With Anti‑Angiogenic Drugs

By Production Technology

• Original
• Generic

By Sales Channels

• Hospital
• Retail
• Online

By Application

• Advanced Non-Small Cell Lung Cancer (NSCLC)
• Brain Metastases
• Others

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Key Vendors

The following companies have been profiled based on primary expert input and analysis of company coverage, product portfolio, and market penetration:

• GenFleet Therapeutics
• Innovent Biologics
• Pharmaron Ningbo manufacturing site

Key Questions Addressed

• What is the 10-year outlook for the global Forzeset Tablets market?
• What factors are driving Forzeset Tablets market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Forzeset Tablets market opportunities vary by end market size?
• How does Forzeset Tablets break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Forzeset Tablets Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Forzeset Tablets by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Forzeset Tablets by Country/Region, 2021, 2025 & 2032

  • 2.2 Forzeset Tablets Segment by Type

    • 2.2.1 150mg

    • 2.2.2 500mg

    • 2.2.3 Forzeset Tablets Sales by Type

      • 2.2.3.1 Global Forzeset Tablets Sales Market Share by Type (2021-2026)
      • 2.2.3.2 Global Forzeset Tablets Revenue and Market Share by Type (2021-2026)
      • 2.2.3.3 Global Forzeset Tablets Sale Price by Type (2021-2026)

  • 2.3 Forzeset Tablets Segment by Combination Therapy

    • 2.3.1 Combined With Immune Checkpoint Inhibitors

    • 2.3.2 Combined With Anti‑Angiogenic Drugs

    • 2.3.3 Forzeset Tablets Sales by Combination Therapy

      • 2.3.3.1 Global Forzeset Tablets Sales Market Share by Combination Therapy (2021-2026)
      • 2.3.3.2 Global Forzeset Tablets Revenue and Market Share by Combination Therapy (2021-2026)
      • 2.3.3.3 Global Forzeset Tablets Sale Price by Combination Therapy (2021-2026)

  • 2.4 Forzeset Tablets Segment by Production Technology

    • 2.4.1 Original

    • 2.4.2 Generic

    • 2.4.3 Forzeset Tablets Sales by Production Technology

      • 2.4.3.1 Global Forzeset Tablets Sales Market Share by Production Technology (2021-2026)
      • 2.4.3.2 Global Forzeset Tablets Revenue and Market Share by Production Technology (2021-2026)
      • 2.4.3.3 Global Forzeset Tablets Sale Price by Production Technology (2021-2026)

  • 2.5 Forzeset Tablets Segment by Sales Channels

    • 2.5.1 Hospital

    • 2.5.2 Retail

    • 2.5.3 Online

    • 2.5.4 Forzeset Tablets Sales by Sales Channels

      • 2.5.4.1 Global Forzeset Tablets Sales Market Share by Sales Channels (2021-2026)
      • 2.5.4.2 Global Forzeset Tablets Revenue and Market Share by Sales Channels (2021-2026)
      • 2.5.4.3 Global Forzeset Tablets Sale Price by Sales Channels (2021-2026)

  • 2.6 Forzeset Tablets Segment by Application

    • 2.6.1 Advanced Non-Small Cell Lung Cancer (NSCLC)

    • 2.6.2 Brain Metastases

    • 2.6.3 Others

    • 2.6.4 Forzeset Tablets Sales by Application

      • 2.6.4.1 Global Forzeset Tablets Sale Market Share by Application (2021-2026)
      • 2.6.4.2 Global Forzeset Tablets Revenue and Market Share by Application (2021-2026)
      • 2.6.4.3 Global Forzeset Tablets Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Forzeset Tablets Breakdown Data by Company

    • 3.1.1 Global Forzeset Tablets Annual Sales by Company (2021-2026)

    • 3.1.2 Global Forzeset Tablets Sales Market Share by Company (2021-2026)

  • 3.2 Global Forzeset Tablets Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Forzeset Tablets Revenue by Company (2021-2026)

    • 3.2.2 Global Forzeset Tablets Revenue Market Share by Company (2021-2026)

  • 3.3 Global Forzeset Tablets Sale Price by Company

  • 3.4 Key Manufacturers Forzeset Tablets Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Forzeset Tablets Product Location Distribution

    • 3.4.2 Players Forzeset Tablets Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Forzeset Tablets by Geographic Region

  • 4.1 World Historic Forzeset Tablets Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Forzeset Tablets Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Forzeset Tablets Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Forzeset Tablets Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Forzeset Tablets Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Forzeset Tablets Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Forzeset Tablets Sales Growth

  • 4.4 APAC Forzeset Tablets Sales Growth

  • 4.5 Europe Forzeset Tablets Sales Growth

  • 4.6 Middle East & Africa Forzeset Tablets Sales Growth

• 5 Americas

  • 5.1 Americas Forzeset Tablets Sales by Country

    • 5.1.1 Americas Forzeset Tablets Sales by Country (2021-2026)

    • 5.1.2 Americas Forzeset Tablets Revenue by Country (2021-2026)

  • 5.2 Americas Forzeset Tablets Sales by Type (2021-2026)

  • 5.3 Americas Forzeset Tablets Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Forzeset Tablets Sales by Region

    • 6.1.1 APAC Forzeset Tablets Sales by Region (2021-2026)

    • 6.1.2 APAC Forzeset Tablets Revenue by Region (2021-2026)

  • 6.2 APAC Forzeset Tablets Sales by Type (2021-2026)

  • 6.3 APAC Forzeset Tablets Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Forzeset Tablets by Country

    • 7.1.1 Europe Forzeset Tablets Sales by Country (2021-2026)

    • 7.1.2 Europe Forzeset Tablets Revenue by Country (2021-2026)

  • 7.2 Europe Forzeset Tablets Sales by Type (2021-2026)

  • 7.3 Europe Forzeset Tablets Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Forzeset Tablets by Country

    • 8.1.1 Middle East & Africa Forzeset Tablets Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Forzeset Tablets Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Forzeset Tablets Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Forzeset Tablets Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Forzeset Tablets

  • 10.3 Manufacturing Process Analysis of Forzeset Tablets

  • 10.4 Industry Chain Structure of Forzeset Tablets

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Forzeset Tablets Distributors

  • 11.3 Forzeset Tablets Customer

• 12 World Forecast Review for Forzeset Tablets by Geographic Region

  • 12.1 Global Forzeset Tablets Market Size Forecast by Region

    • 12.1.1 Global Forzeset Tablets Forecast by Region (2027-2032)

    • 12.1.2 Global Forzeset Tablets Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Forzeset Tablets Forecast by Type (2027-2032)

  • 12.7 Global Forzeset Tablets Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 GenFleet Therapeutics

    • 13.1.1 GenFleet Therapeutics Company Information

    • 13.1.2 GenFleet Therapeutics Forzeset Tablets Product Portfolios and Specifications

    • 13.1.3 GenFleet Therapeutics Forzeset Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 GenFleet Therapeutics Main Business Overview

    • 13.1.5 GenFleet Therapeutics Latest Developments

  • 13.2 Innovent Biologics

    • 13.2.1 Innovent Biologics Company Information

    • 13.2.2 Innovent Biologics Forzeset Tablets Product Portfolios and Specifications

    • 13.2.3 Innovent Biologics Forzeset Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Innovent Biologics Main Business Overview

    • 13.2.5 Innovent Biologics Latest Developments

  • 13.3 Pharmaron Ningbo manufacturing site

    • 13.3.1 Pharmaron Ningbo manufacturing site Company Information

    • 13.3.2 Pharmaron Ningbo manufacturing site Forzeset Tablets Product Portfolios and Specifications

    • 13.3.3 Pharmaron Ningbo manufacturing site Forzeset Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Pharmaron Ningbo manufacturing site Main Business Overview

    • 13.3.5 Pharmaron Ningbo manufacturing site Latest Developments

• 14 Research Findings and Conclusion